India, Nov. 11 -- Eli Lilly and Company (LLY) announced on Wednesday, 52-week results from its TOGETHER-PsA Phase 3b trial, showing improved and sustained outcomes among adults with active psoriatic arthritis and obesity or overweight who received Taltz and Zepbound together compared with Taltz alone.
At one year, 43.7 percent of patients receiving the combination achieved ACR50, indicating at least a 50 percent improvement in disease activity, compared with 15.7 percent among those taking Taltz alone.
The combination also produced greater improvements in weight reduction, physical function, fatigue and metabolic measures, including blood pressure, glucose and cholesterol.
The 52-week findings build on results showing that the combinatio...